Logo
    Search

    Podcast Summary

    • Ozempic and similar drugs causing a stir for weight loss capabilitiesGLP-1 class drugs, initially for blood sugar regulation, induce weight loss as a side effect, gaining popularity due to obesity being a major public health concern and cultural interest in weight loss solutions

      Ozempic and similar drugs are causing a significant stir in both the medical and cultural spheres due to their effective weight loss capabilities. These drugs, which belong to the GLP-1 class, were initially developed to regulate blood sugar and insulin but were found to induce weight loss as a side effect. With obesity being a major public health concern and a cultural conversation around body image ongoing, the arrival of Ozempic and similar drugs has introduced a new dimension to these discussions. The drug's widespread popularity, as evidenced by its prevalence in social media and advertising, highlights the growing interest and need for effective weight loss solutions.

    • Ozempic's ability to aid weight lossOzempic, used for type 2 diabetes, aids significant weight loss by mimicking a hormone and targeting appetite regulation areas. However, its high demand for weight management has led to shortages for those who need it for diabetes.

      The once-weekly injectable drug Ozempic, approved for type 2 diabetes, has been found to help people lose significant weight. This occurs due to the medication's ability to mimic a naturally occurring hormone, making users feel fuller for longer and targeting the brain's appetite regulation areas. However, if stopped, the weight loss may be reversed. The FDA approved Wegovy for weight management in 2021, leading to increased demand for Ozempic as a weight loss alternative. Despite not being officially approved for weight loss, many people and doctors seek it out, often paying high out-of-pocket costs due to insurance limitations. The high demand has led to drug shortages for those who genuinely need it for diabetes management.

    • Discovering Weight Loss Drugs on Social MediaSocial media and celebrity endorsements have shifted the focus of weight loss drugs from managing diabetes to weight loss, potentially overshadowing their original purpose and leading to a damaging emphasis on thinness.

      The popularity of weight loss drugs like Ozempic and Wegovy has skyrocketed due to social media buzz and celebrity endorsements, shifting the focus from managing diabetes to weight loss. This trend raises important questions about our society's relationship with weight and health. For instance, Wendy Gant, a mental health counselor in her fifties, discovered these drugs on TikTok and saw them as a potential solution to her lifelong struggle with weight. She had tried numerous diets since childhood and, as an adult, her weight issue became a medical concern when her cholesterol levels rose. Another woman, whose story will be shared later, also experienced significant life changes after taking these drugs. The mainstream conversation around these medications is now primarily centered on weight loss, which could potentially overshadow their original purpose. It's crucial to strike a balance between promoting health and avoiding the psychologically damaging emphasis on being excessively thin. As these drugs become more prevalent, individuals taking them must grapple with the implications and meaning behind their use.

    • Manjaro helps quiet the constant mental chatter around foodManjaro medication can bring significant relief from constant food preoccupation, leading to increased success in implementing healthy habits and substantial weight loss

      For some individuals, particularly those struggling with weight despite diet and exercise efforts, the medication Manjaro (similar to Ozempic) can bring about a significant shift in their relationship with food. This shift is described as a quieting of the constant mental chatter around food, allowing individuals to focus on other aspects of their health and wellbeing. This relief can lead to increased success in implementing long-term healthy habits, resulting in substantial weight loss. For instance, the woman in the discussion lost 40 pounds after beginning the medication. This transformation can be compared to the reduction in anxiety noise experienced by those taking antianxiety medication. Overall, Manjaro offers a promising solution for those seeking to improve their relationship with food and achieve weight loss goals.

    • Two women, two different weight loss journeysEvery weight loss journey is unique, with some finding relief through medication while others focus on intuitive eating, ultimately leading to self-acceptance and peace with their bodies.

      While weight loss medications can bring significant physical improvements for some individuals, the experience is not the same for everyone. For Wendy, a medication for her arthritis led to a 20% weight loss and alleviation of her joint pain. However, she doesn't grapple much with the larger questions of self-acceptance and body positivity. In contrast, Renata, diagnosed with PCOS, found relief through intuitive eating, which helped her stop dieting and focus on foods that made her feel good. Her journey led her to peace with her body, but a doctor's visit introduced her to a weight loss medication she hadn't sought out. Both women's stories illustrate that weight loss journeys are complex and multifaceted, and there's no one-size-fits-all solution.

    • Personal determination to stick with medication despite side effectsIndividuals may continue taking medications despite severe side effects, emphasizing the importance of being informed and the resilience shown in managing health.

      Renata, unlike some people, relies on her doctor's advice to try new medications, even when the side effects are severe. In this case, she began taking Ozempic for weight loss and experienced extreme nausea and difficulty digesting food. Despite feeling sick and having a hard time eating, she continued taking the medication due to the investment she had made and the belief that it could eventually benefit her. Unfortunately, the medication caused her to become malnourished due to her inability to eat enough. This experience highlights the importance of being informed about medications and their potential side effects, as well as the determination and resilience that some individuals show in managing their health despite challenges.

    • Unexpected challenges with weight loss medicationsWeight loss medications like Ozempic can lead to unexpected challenges such as malnourishment and a complicated relationship with food. Individuals must weigh the risks and benefits before deciding to continue or discontinue use.

      The use of weight loss medications like Ozempic can bring about unexpected challenges, including malnourishment and a complicated relationship with food. Renata's experience of losing little weight while struggling with appetite and nutrient intake was starkly different from Wendy's reported success. Although malnourishment is rare, it highlights the potential side effects that individuals may face when deciding to use these medications. The decision to continue or discontinue use depends on the individual's assessment of the risks and benefits. Renata's experience of becoming preoccupied with food while on the medication led her to question her progress in separating her self-worth from her weight. This shift in perspective, while intended to promote weight loss, ultimately complicated her relationship with food and her mental health. The widespread use of these medications underscores a significant cultural shift in attitudes towards weight and obesity, moving away from viewing it as a moral failing and towards a more nuanced understanding of health and wellness.

    • The moral implications of weight loss medicationsWeight loss medications like Ozempic raise moral questions, offering potential solutions to obesity while reinforcing societal expectations of thinness and creating new layers of stigma

      The availability of weight loss medications like Ozempic raises complex questions about morality, personal choice, and societal stigma surrounding obesity. While some argue that these medications can help remove the moral judgment associated with obesity and offer a medical solution to a chronic condition, others worry that they may reinforce societal expectations of thinness and create new layers of stigma for those who cannot or choose not to use them. As the pharmaceutical industry continues to develop and approve more weight loss drugs, it's crucial to consider the potential psychological and cultural implications, including the impact on individuals' relationships with food and their bodies, as well as the broader societal conversations around weight and health. Ultimately, it's essential to approach this issue with a nuanced understanding of the complex interplay between personal choice, medical intervention, and societal expectations.

    • Impeachment trial of Texas AG Ken Paxton tests GOP loyaltyDespite serious allegations, Republican officials faced intense pressure to acquit Texas AG Ken Paxton during his impeachment trial, highlighting the challenges of using impeachment to oust a sitting GOP figure.

      The impeachment trial of Texas Attorney General Ken Paxton served as a test of Republican Party loyalty during the hyperpartisan era of Donald Trump. Paxton, a Trump ally, was impeached by the Republican-controlled Texas House over allegations of office abuse, but was acquitted by the Texas Senate this weekend amid intense pressure from national conservatives. The trial highlighted the challenges of using the impeachment process to oust a sitting Republican official, even in the face of serious allegations. The episode was produced by Nina Feldman and Alex Stern, edited by Lexi Diao, fact checked by Susan Lee, and engineered by Alissa Moxley, with original music by Marion Lozano, Rowan Emisto, Diane Wong, and Alicia Batitub. Our theme music is by Brunsberg and Ben Landsberg of Wonderlane.

    Recent Episodes from The Daily

    Loving Their Pets to Debt

    Loving Their Pets to Debt

    Over the past decade, the cost of veterinary care in the U.S. has skyrocketed, as health care for pets has come to look more like health care for people.

    Katie Thomas, an investigative health care reporter for The Times, discusses how pet care became a multi-billion-dollar industry, and the fraught emotional and financial landscape that has created for pet owners.

    Guest: Katie Thomas, an investigative health care reporter for The New York Times.

    Background reading: 

    For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday. 

    The Daily
    enJuly 12, 2024

    72 Hours Inside Biden’s Campaign to Save His Candidacy

    72 Hours Inside Biden’s Campaign to Save His Candidacy

    For the past three days, President Biden has fought to save his re-election campaign, as panicked congressional Democrats returned to Washington and openly debated whether to call on him to step aside.

    In this episode, Times reporters in Washington go inside the 72 hours that could make or break Mr. Biden’s nomination.

    Guest: 

    • Representative Adam Smith, of the 9th Congressional District in Washington

    Background reading: 

    For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday. 

    The Daily
    enJuly 11, 2024

    Why Britain Just Ended 14 Years of Conservative Rule

    Why Britain Just Ended 14 Years of Conservative Rule

    For more than a decade, Britain has been governed by the Conservative Party, which pushed its politics to the right, embracing smaller government and Brexit. Last week, that era officially came to an end.

    Mark Landler, the London bureau chief for The Times, explains why British voters rejected the Conservatives and what their defeat means in a world where populism is on the rise.

    Guest: Mark Landler, the London bureau chief for The New York Times.

    Background reading: 

    For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday. 

    The Daily
    enJuly 10, 2024

    The Era of Killer Robots Is Here

    The Era of Killer Robots Is Here

    Outmanned and outgunned in what has become a war of attrition against Russia, Ukraine has looked for any way to overcome its vulnerabilities on the battlefield. That search has led to the emergence of killer robots.

    Paul Mozur, the global technology correspondent for The Times, explains how Ukraine has become a Silicon Valley for autonomous weapons and how artificial intelligence is reshaping warfare.

    Guest: Paul Mozur, the global technology correspondent for The New York Times.

    Background reading:

    For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.

    The Daily
    enJuly 09, 2024

    The Supreme Court Is Not Done Remaking America

    The Supreme Court Is Not Done Remaking America

    When the Supreme Court wrapped up its term last week, much of the focus was one the ruling that gave former President Donald J. Trump sweeping immunity from criminal prosecution. But another set of rulings that generated less attention could have just as big an impact on American government and society.

    Adam Liptak, who covers the Supreme Court for The Times, looks back at the Supreme Court term.

    Guest: Adam Liptak, , who covers the Supreme Court for The New York Times and writes Sidebar, a column on legal developments.

    Background reading: 

    For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.

    The Daily
    enJuly 08, 2024

    'Animal,' Episode 6: Bats

    'Animal,' Episode 6: Bats

    On the final episode of “Animal,” Sam Anderson travels to Mexico’s Yucatán Peninsula to meet with a creature he's long been afraid of: bats.

    For photos and videos of Sam's journey to the Yucatán, and to listen to the full series, visit nytimes.com/animal. You can search for “Animal” wherever you get your podcasts. 

    The Daily
    enJuly 07, 2024

    How Bad Is Drinking for You, Really?

    How Bad Is Drinking for You, Really?

    Midway through one of the booziest holiday weekends of the year, we re-examine our love-hate relationship with alcohol.

    Susan Dominus, a staff writer for The New York Times Magazine, gets to the bottom of the conflicting guidance on the benefits and risks of drinking.

    Guest: Susan Dominus, a staff writer for The New York Times Magazine.

    Background reading: 

    For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday

    The Daily
    enJuly 05, 2024

    Biden’s Slipping Support

    Biden’s Slipping Support

    A major Times poll has found that voters’ doubts about President Biden deepened after his poor performance in the first debate, with Donald J. Trump taking by far his biggest lead of the campaign.

    Shane Goldmacher, a national political correspondent for The Times, explains what those results could mean for Mr. Biden’s future.

    Guest: Shane Goldmacher, a national political correspondent for The New York Times.

    Background reading: 

    For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.

    The Daily
    enJuly 04, 2024

    The American Journalist on Trial in Russia

    The American Journalist on Trial in Russia

    Evan Gershkovich, an American journalist for The Wall Street Journal, was detained in Russia more than a year ago. He has been locked up in a high-security prison and accused of spying for the U.S. government.

    His trial, held in secret, is now underway.

    Anton Troianovski, the Moscow bureau chief for The New York Times, discusses the complicated geopolitics behind Mr. Gershkovich’s detention and the efforts to get him home.

    Guest: Anton Troianovski, the Moscow bureau chief for The New York Times.

    Background reading: 

    For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.

    The Daily
    enJuly 03, 2024

    Trump Wins Broad Immunity

    Trump Wins Broad Immunity

    On Monday, the Supreme Court ruled that former President Donald J. Trump is entitled to broad immunity from criminal prosecution for actions that he took while in office.

    Adam Liptak, who covers the Supreme Court for The New York Times, explains how that ruling will weaken the federal case against Mr. Trump for trying to overturn the last U.S. presidential election, and will drastically expand the power of the presidency itself.

    Guest: Adam Liptak, a Supreme Court correspondent for The New York Times.

    Background reading: 

    For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.

    The Daily
    enJuly 02, 2024

    Related Episodes

    Ozempic

    Ozempic

    Ozempic is being hailed as “the end of the Obesity Epidemic.” This week, Mike and Aubrey dig through the sensational claims. But will they make it past the caveats?

    Links: 

    Thanks to Doctor Dreamchip for our lovely theme song!

    Support the show

    JP Morgan Healthcare Conference Highlights

    JP Morgan Healthcare Conference Highlights
    Weight loss drugs are taking center spotlight, but other developing treatments could change how we live. Deidre Woollard caught up with Motley Fool biotech analyst Karl Thiel to discuss: - Biogen’s next shot at an Alzheimer’s treatment. - Why companies can’t “muscle their way” into making new molecules. - How NVIDIA could change drug development.  - Moderna’s vaccine strategy Companies discussed: LLY, NVO, GPCR, NVDA, DXCM, NVDA, BIIB, GEHC, MRNA, NVCR, VRTX Host: Deidre Woollard Guest: Karl Thiel Producer: Ricky Mulvey Engineer: Tim Sparks Learn more about your ad choices. Visit megaphone.fm/adchoices

    Here's How the New Weight Loss Drugs Could Change Everything

    Here's How the New Weight Loss Drugs Could Change Everything

    There's a new class of weight-loss drugs in town. GLP-1 medications including Ozempic, Wegovy and Mounjaro were created to treat diabetes but have since been found to suppress appetites and induce substantial weight loss. It's a big deal for the companies which make them, with shares of Novo Nordisk and Eli Lilly all soaring in recent weeks. But the drugs could end up having a much broader economic impact too. On this episode, we speak with James van Geelen of Citrinitas Capital, about the second-order effects of effective weight-loss drugs. He talks us through how he's evaluating the potential of the new meds and how he approaches possible 'mega-trends' like GLP-1 or AI.

    See omnystudio.com/listener for privacy information.

    How the Rise of Ozempic Will Affect the Food Industry

    How the Rise of Ozempic Will Affect the Food Industry

    Today I’m deep-diving on all things GLP-1 agonist medications and forecasting their impact on the CPG food and beverage industry for 2024 and beyond. Specifically, I discuss: 

    • How GLP-1’s change individuals’ food preferences, overall intake, and alter taste perception 

    • How the rise of GLP-1’s as the pharmaceutical industry’s “blockbuster” might affect the food industry in the short and long-term, and how food companies could start to approach this topic as they prepare their product roadmaps for the future

    • What are some specific concerns among individuals taking GLP-1’s as it relates to food and beverage products, and their own personal tolerance to specific foods in light of medication side effects?

    • GLP-1’s and early satiety: We discuss how the medications create feelings of early satiety– what this means for practitioners, how this affects individual patients, and how the MNT for GERD and early satiety may be beneficial when considering / seeking to understand this patient population more effectively

    • Alcohol, coffee, single-serve convenience foods, sugar-sweetened beverages, tomato-based products, eggs, veggies and fruit, and high saturated fat, high refined carb food products– what do all of these products have in common, and which ones of these will be better tolerated by individuals taking GLP-1’s vs. not

    • Side effects of GLP-1’s that affect diet and lifestyle, and how these translate to CPG foo and beverage industries and product roadmaps/financial forecasting 

    • My most fascinating finding of all: How tolerance to GLP-1 medications may be promoted through nutrition education & adopting diet & lifestyle shifts BEFORE STARTING the medication vs. referring to a dietitian/receiving nutrition education AFTER starting a GLP-1. I talk about why the lack of nutrition education & counseling may be affecting medication tolerance and ultimately, affecting a patient’s ability to adhere to the medication long-term due to diet-related side effects.

    • The foods & beverages NOT AFFECTED by GLP-1’s that still demand attention for the sake of helping individuals achieve better cardiometabolic health. 

     

    🎙️Follow The Business of Wellness on Apple Podcasts & leave a 5-star rating & review 

    🎙️Hire me to consult before you invest in or get to work on that “better-for-you” product  

    🎙️Follow me @jaclynlondonrd

    🎙️Krispy Kreme article from Forbes

    🎙️Are GLP-1’s the root cause of consumer shopping shifts? WaPo thinks so (but I’m not sold)

     

    Advice provided on this podcast should not replace medical advice provided by your physician. 

    How the Rise of Ozempic Will Affect the Food Industry

    How the Rise of Ozempic Will Affect the Food Industry

    Today I’m deep-diving on all things GLP-1 agonist medications and forecasting their impact on the CPG food and beverage industry for 2024 and beyond. Specifically, I discuss: 

    • How GLP-1’s change individuals’ food preferences, overall intake, and alter taste perception 

    • How the rise of GLP-1’s as the pharmaceutical industry’s “blockbuster” might affect the food industry in the short and long-term, and how food companies could start to approach this topic as they prepare their product roadmaps for the future

    • What are some specific concerns among individuals taking GLP-1’s as it relates to food and beverage products, and their own personal tolerance to specific foods in light of medication side effects?

    • GLP-1’s and early satiety: We discuss how the medications create feelings of early satiety– what this means for practitioners, how this affects individual patients, and how the MNT for GERD and early satiety may be beneficial when considering / seeking to understand this patient population more effectively

    • Alcohol, coffee, single-serve convenience foods, sugar-sweetened beverages, tomato-based products, eggs, veggies and fruit, and high saturated fat, high refined carb food products– what do all of these products have in common, and which ones of these will be better tolerated by individuals taking GLP-1’s vs. not

    • Side effects of GLP-1’s that affect diet and lifestyle, and how these translate to CPG foo and beverage industries and product roadmaps/financial forecasting 

    • My most fascinating finding of all: How tolerance to GLP-1 medications may be promoted through nutrition education & adopting diet & lifestyle shifts BEFORE STARTING the medication vs. referring to a dietitian/receiving nutrition education AFTER starting a GLP-1. I talk about why the lack of nutrition education & counseling may be affecting medication tolerance and ultimately, affecting a patient’s ability to adhere to the medication long-term due to diet-related side effects.

    • The foods & beverages NOT AFFECTED by GLP-1’s that still demand attention for the sake of helping individuals achieve better cardiometabolic health. 

     

    🎙️Follow The Business of Wellness on Apple Podcasts & leave a 5-star rating & review 

    🎙️Hire me to consult before you invest in or get to work on that “better-for-you” product  

    🎙️Follow me @jaclynlondonrd

    🎙️Krispy Kreme article from Forbes

    🎙️Are GLP-1’s the root cause of consumer shopping shifts? WaPo thinks so (but I’m not sold)

     

    Advice provided on this podcast should not replace medical advice provided by your physician.